Search research articles
Contact Us
Filters
Showing results (21-30 of 135) with videos related to
Page
of 14
Sort By:
Health Policy and Planning
|
February 17, 2017
The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa
Don Mudzengi, Sedona Sweeney, Piotr Hippner, et al.
BMC Public Health
|
October 30, 2025
Frequency of tuberculosis symptoms at repeat visits amongst adults attending for HIV care in Gauteng province, South Africa
Thobani Ntshiqa, Sena Jawad, Yasmeen Hanifa, et al.
Plos One
|
February 12, 2019
Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa
Natasha Pillai, Nicola Foster, Yasmeen Hanifa, et al.
International Journal of Epidemiology
|
March 5, 2026
Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials
Daniel J Grint, Richard G White, Gavin Churchyard, et al.
The Journal of Infectious Diseases
|
November 8, 2017
What We Know About Tuberculosis Transmission: An Overview
Gavin Churchyard, Peter Kim, N Sarita Shah, et al.
Plos One
|
June 21, 2016
Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis
Swati Jha, Nazir Ismail, David Clark, et al.
The Lancet. Global Health
|
June 17, 2017
Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
Anna Vassall, Mariana Siapka, Nicola Foster, et al.
Plos Medicine
|
September 2, 2015
The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis
Gesine Meyer-Rath, Jan Pienaar, Brian Brink, et al.
Antiviral Therapy
|
August 26, 2009
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa
Karen Cohen, Alison Grant, Collet Dandara, et al.
Plos One
|
March 4, 2014
Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection
Andre S Nell, Eva D'lom, Patrick Bouic, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 135) with videos related to
Sort By:
Page
of 14
Health Policy and Planning
|
February 17, 2017
The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa
Don Mudzengi, Sedona Sweeney, Piotr Hippner, et al.
BMC Public Health
|
October 30, 2025
Frequency of tuberculosis symptoms at repeat visits amongst adults attending for HIV care in Gauteng province, South Africa
Thobani Ntshiqa, Sena Jawad, Yasmeen Hanifa, et al.
Plos One
|
February 12, 2019
Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa
Natasha Pillai, Nicola Foster, Yasmeen Hanifa, et al.
International Journal of Epidemiology
|
March 5, 2026
Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials
Daniel J Grint, Richard G White, Gavin Churchyard, et al.
The Journal of Infectious Diseases
|
November 8, 2017
What We Know About Tuberculosis Transmission: An Overview
Gavin Churchyard, Peter Kim, N Sarita Shah, et al.
Plos One
|
June 21, 2016
Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis
Swati Jha, Nazir Ismail, David Clark, et al.
The Lancet. Global Health
|
June 17, 2017
Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
Anna Vassall, Mariana Siapka, Nicola Foster, et al.
Plos Medicine
|
September 2, 2015
The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis
Gesine Meyer-Rath, Jan Pienaar, Brian Brink, et al.
Antiviral Therapy
|
August 26, 2009
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa
Karen Cohen, Alison Grant, Collet Dandara, et al.
Plos One
|
March 4, 2014
Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection
Andre S Nell, Eva D'lom, Patrick Bouic, et al.
Page
of 14